Search

SX-682

SX-682 is under investigation in clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp … Alfa (M7824 or Tgf-beta "Trap"/pd-l1) With CV301 TRICOM in Advanced Solid Tumors (STAT)).

Methylmalonic Acid

A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. … This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA. [PubChem]

Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

Abdavomeran

[L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15007, L15012] Early results from a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID

Amredobresib

Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies). Amredobresib has a monoisotopic molecular weight of 467.25 Da. … The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

Tegtociclib

Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid … The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor.

IMM101

As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).

Laronidase

It contains 6 N-linked oligosaccharide modification sites. … Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.

Brilaroxazine

As of May 2015, it is in phase III clinical trials for schizophrenia. … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.